HoLEP Feasible for BPH Patients With Low-risk Prostate Cancer May 13, 2017 For obstructive benign prostatic hyperplasia (BPH) patients with concurrent low risk T1a or b prostate cancer (PCa), holmium laser enucleation of the prostate (HoLEP) appears to be safe and effective, according to new study findings presented at the American Urological Association 2017 annual meeting.Read more.Source: Renal and Urology News Prostate Cancer News
For obstructive benign prostatic hyperplasia (BPH) patients with concurrent low risk T1a or b prostate cancer (PCa), holmium laser enucleation of the prostate (HoLEP) appears to be safe and effective, according to new study findings presented at the American Urological Association 2017 annual meeting.Read more.Source: Renal and Urology News
